Tildrakizumab-asmn

Tildrakizumab-asmn Uses, Dosage, Side Effects, Food Interaction and all others data.

Tildrakizumab-asmn is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .

The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter .

A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects .

Trade Name Tildrakizumab-asmn
Availability Prescription only
Generic Tildrakizumab
Tildrakizumab Other Names Tildrakizumab, tildrakizumab-asmn
Related Drugs Humira, Otezla, Cosentyx, methotrexate, Enbrel, Remicade, Stelara, cyclosporine, infliximab
Type Subcutaneous
Formula C6426H9918N1698O2000S46
Weight 144400.0 Da
Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Tildrakizumab-asmn
Tildrakizumab-asmn

Uses

Tildrakizumab-asmn is an interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.

Moderate-severe plaque psoriasis , .

Tildrakizumab-asmn is also used to associated treatment for these conditions: Moderate-to-severe Plaque Psoriasis

How Tildrakizumab-asmn works

This drug selectively binds interleukin (IL)-23 p19 subunit of cytokine IL-23 and neutralizes its function IL-23 regulates Th17 cells and is a powerful activator of keratinocyte proliferation . Targeting IL-23p19 alone has been found to be a promising treatment approach in patients with moderate-to-severe chronic plaque psoriasis. Upon administration, downregulation of Th17 and Th22 cell responses occur .

IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab-asmn inhibits the release of proinflammatory cytokines and chemokines .

Toxicity

It is advised to evaluate patients for tuberculosis infection prior to initiating treatment with ILUMYA. This drug may increase the risk of infection . It is advisable to perform tests for current tuberculosis status, as this drug may lead to reactivation of latent infection .

A common issue for monoclonal antibody drugs is the development of antibodies to the drugs, thus rendering them less effective or completely ineffective . A clinical trial was done to assess antibody development to this drug , . Up until week 64, approximately 6.5% of subjects treated with ILUMYA 100 mg developed antibodies to tildrakizumab. Of the subjects who developed antibodies to tildrakizumab, approximately 40% (2.5% of all patients receiving ILUMYA) had antibodies that were considered neutralizing. The development of neutralizing antibodies to tildrakizumab was associated with lower serum tildrakizumab concentrations and decreased efficacy .

Most common (≥ 1% and at a higher rate than placebo) adverse reactions associated with ILUMYA treatment are upper respiratory infections, injection site reactions, and diarrhea .

Cases of angioedema and urticaria occurred in ILUMYA treated subjects in various clinical trials. If a hypersensitivity reaction occurs, the drug should be discontinued immediately and appropriate therapy should be initiated .

In an embryo-fetal study, subcutaneous doses up to 300 mg/kg tildrakizumab were given to pregnant cynomolgus monkeys once every two weeks during organogenesis to 118 days gestation (22 days from parturition). No maternal or embryo-fetal toxicities were seen at doses up to 300 mg/kg (159 times the MRHD of 100 mg, based on AUC comparison). Tildrakizumab-asmn crossed the placenta in monkeys .

Food Interaction

No interactions found.

Tildrakizumab-asmn Disease Interaction

Major: tuberculosisModerate: infections, vaccination

Volume of Distribution

The geometric mean (CV%) volume of distribution is 10.8 L (24%) .

Elimination Route

The mean (± SD) steady-state trough concentrations at 16 weeks post initiation of treatment ranged from 1.22 ± 0.94 mcg/mL to 1.47 ± 1.12 mcg/mL. The geometric mean (CV%) steady-state Cmax was 8.1 mcg/mL (34%) .

The absolute bioavailability of tildrakizumab is estimated to be about 73-80% after subcutaneous administration. The peak concentration (Cmax) is reached by approximately 6 days .

Half Life

The half-life is approximately 23 days (23%) .

Clearance

The mean (CV%) systemic clearance is 0.32 L/day (38%) .

Innovators Monograph

You find simplified version here Tildrakizumab-asmn

*** Taking medicines without doctor's advice can cause long-term problems.
Share